GlassScriptPhysician profile
Jacinto A Obregon
NPI 1396936019
$2,718.45
in general payments reported to CMS, 2019-2025
26 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.30 · 2020: $103 · 2024: $1,318 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $411.37 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $408.77 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $334.04 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.63 | 2024-2025 | Jardiance |
| Pfizer INC. | $247.11 | 2024-2025 | |
| Amgen INC. | $196.38 | 2024-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $141.85 | 2024-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $97.19 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $86.56 | 2019-2025 | Airsupra |
| Abbott Laboratories | $64.31 | 2024-2025 | Proclaim |
| Dexcom, INC. | $57.46 | 2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $55.29 | 2024-2025 | Vanta Adaptivestim, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $47.56 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ultragenyx Pharmaceutical INC. | $46.11 | 2024 | Crysvita |
| Astellas Pharma US INC | $39.75 | 2024 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $36.90 | 2024 | |
| Inspire Medical Systems, INC. | $32.51 | 2025 | Inspire |
| Tris Pharma INC | $24.90 | 2025 | Dyanavel Xr |
| Hologic Sales and Service, LLC | $20.33 | 2024 | Aptima |
| Atricure, INC. | $20.31 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Phathom Pharmaceuticals, INC. | $18.10 | 2024 | Voquezna |
| Collegium Pharmaceutical, INC. | $17.25 | 2025 | Jornay Pm |
| Kowa Pharmaceuticals America, INC. | $15.86 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $15.33 | 2024 | Contrave, Onzetra Xsail |
| Glaxosmithkline, LLC. | $15.27 | 2025 | Trelegy Ellipta |
| Spinal Simplicity, LLC | $14.31 | 2025 | Ha Minuteman G3-R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinto Obregon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.